These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23029387)

  • 1. Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.
    Ma L; Niknejad N; Gorn-Hondermann I; Dayekh K; Dimitroulakos J
    PLoS One; 2012; 7(9):e46055. PubMed ID: 23029387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.
    Mantha AJ; McFee KE; Niknejad N; Goss G; Lorimer IA; Dimitroulakos J
    J Cancer Res Clin Oncol; 2003 Nov; 129(11):631-41. PubMed ID: 12942316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal.
    Niknejad N; Gorn-Hondermann I; Ma L; Zahr S; Johnson-Obeseki S; Corsten M; Dimitroulakos J
    Int J Cancer; 2014 Jan; 134(2):268-79. PubMed ID: 23824972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
    Yang SH; Lin HY; Chang VH; Chen CC; Liu YR; Wang J; Zhang K; Jiang X; Yen Y
    Oncotarget; 2015 Sep; 6(27):23857-73. PubMed ID: 26160843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
    Mantha AJ; Hanson JE; Goss G; Lagarde AE; Lorimer IA; Dimitroulakos J
    Clin Cancer Res; 2005 Mar; 11(6):2398-407. PubMed ID: 15788691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
    Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
    Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lovastatin-mediated MCF-7 cancer cell death involves LKB1-AMPK-p38MAPK-p53-survivin signalling cascade.
    Huang SW; Chyuan IT; Shiue C; Yu MC; Hsu YF; Hsu MJ
    J Cell Mol Med; 2020 Jan; 24(2):1822-1836. PubMed ID: 31821701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imiquimod-induced AMPK activation causes translation attenuation and apoptosis but not autophagy.
    Wang ST; Huang SW; Kao JK; Liang SM; Chen YJ; Chen YY; Wu CY; Shieh JJ
    J Dermatol Sci; 2015 May; 78(2):108-16. PubMed ID: 25766763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway.
    Dimitroulakos J; Lorimer IA; Goss G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4426s-4431s. PubMed ID: 16857822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma.
    Yang SH; Lin HY; Changou CA; Chen CH; Liu YR; Wang J; Jiang X; Luh F; Yen Y
    Oncotarget; 2016 Jan; 7(1):362-73. PubMed ID: 26517522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of β-catenin controls both apoptotic and autophagic cell death through LKB1/AMPK signaling in head and neck squamous cell carcinoma cell lines.
    Chang HW; Lee YS; Nam HY; Han MW; Kim HJ; Moon SY; Jeon H; Park JJ; Carey TE; Chang SE; Kim SW; Kim SY
    Cell Signal; 2013 Apr; 25(4):839-47. PubMed ID: 23280187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.
    Dimitroulakos J; Marhin WH; Tokunaga J; Irish J; Gullane P; Penn LZ; Kamel-Reid S
    Neoplasia; 2002; 4(4):337-46. PubMed ID: 12082550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin impairs the growth of liver kinase B1-intact cervical cancer cells.
    Xiao X; He Q; Lu C; Werle KD; Zhao RX; Chen J; Davis BC; Cui R; Liang J; Xu ZX
    Gynecol Oncol; 2012 Oct; 127(1):249-55. PubMed ID: 22735790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors.
    Zhao TT; Trinh D; Addison CL; Dimitroulakos J
    PLoS One; 2010 Sep; 5(9):e12563. PubMed ID: 20838437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.
    Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
    Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convergence of IPMK and LKB1-AMPK signaling pathways on metformin action.
    Bang S; Chen Y; Ahima RS; Kim SF
    Mol Endocrinol; 2014 Jul; 28(7):1186-93. PubMed ID: 24877601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
    Park IH; Kim JY; Jung JI; Han JY
    Invest New Drugs; 2010 Dec; 28(6):791-9. PubMed ID: 19760159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner.
    Rattan R; Giri S; Hartmann LC; Shridhar V
    J Cell Mol Med; 2011 Jan; 15(1):166-78. PubMed ID: 19874425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells.
    Mondal A; Roberge J; Gilleran J; Peng Y; Jia D; Akel M; Patel Y; Zoltowski H; Doraiswamy A; Langenfeld J
    Cell Commun Signal; 2022 Jun; 20(1):99. PubMed ID: 35761398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.